Literature DB >> 1592175

Determining the optimum residual moisture in lyophilized protein pharmaceuticals.

C C Hsu1, C A Ward, R Pearlman, H M Nguyen, D A Yeung, J G Curley.   

Abstract

A general concern in the lyophilization of protein pharmaceuticals is how dry a product should be in order to maintain its stability during storage. This paper presents our exploratory studies on determining if there is an optimal residual moisture content for lyophilized recombinant protein products. The proteins used in this study were methionyl human growth hormone (met-hGH) and tissue type plasminogen activator (tPA). The amount of water adsorbed on each protein can be determined and approximated as a monolayer by the Brunauer-Emmett-Teller method. The result was in good agreement with the theoretical value calculated from the total number of strong polar groups in the molecule without regard to the conformation of the protein. This approach suggests that each protein may have a minimum moisture content that is necessary to shield the polar groups, and that over-drying will lead to exposure of these groups. The effect of residual moisture content on the stability of tPA in lyophilized excipient-free powder was studied. Samples that were dried to a water content below the calculated monolayer exhibited opalescence upon reconstitution, while those that were dried to either monolayer or multilayer water content tended to show a greater loss in biological stability upon storage under temperature stress conditions. The results of our studies reveal that the generally accepted concept "the drier the better" may not be appropriate for tPA. An optimum residual moisture content is required to balance the physical stability and the biological stability. These observations may apply to other protein products as well.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1592175

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  18 in total

1.  X-ray crystal structures of a severely desiccated protein.

Authors:  J A Bell
Journal:  Protein Sci       Date:  1999-10       Impact factor: 6.725

2.  Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation.

Authors:  E D Breen; J G Curley; D E Overcashier; C C Hsu; S J Shire
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

3.  Development of a remote electrode system for monitoring the water content of materials inside a glass vial.

Authors:  Phe Man Suherman; Peter M Taylor; Geoff Smith
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

4.  Characterization of murine monoclonal antibody to tumor necrosis factor (TNF-MAb) formulation for freeze-drying cycle development.

Authors:  X Ma; D Q Wang; R Bouffard; A MacKenzie
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

5.  Development of a mathematical model for the water distribution in freeze-dried solids.

Authors:  H K Chan; K L Au-Yeung; I Gonda
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

6.  Aggregation of rhDNase occurred during the compression of KBr pellets used for FTIR spectroscopy.

Authors:  H K Chan; B Ongpipattanakul; J Au-Yeung
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

7.  New Method for Monitoring the Process of Freeze Drying of Biological Materials.

Authors:  Nikolay Alkeev; Stanislav Averin; Svetlana von Gratowski
Journal:  AAPS PharmSciTech       Date:  2015-05-29       Impact factor: 3.246

8.  Effect of Particle Formation Process on Characteristics and Aerosol Performance of Respirable Protein Powders.

Authors:  Ashlee D Brunaugh; Tian Wu; Sekhar R Kanapuram; Hugh D C Smyth
Journal:  Mol Pharm       Date:  2019-08-26       Impact factor: 4.939

9.  Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations.

Authors:  James D Andya; Chung C Hsu; Steven J Shire
Journal:  AAPS PharmSci       Date:  2003

10.  Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P [6-11].

Authors:  J D Jonkman-de Vries; H Rosing; H Talsma; R E Henrar; J J Kettenes-van den Bosch; A Bult; J H Beijnen
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.